슬롯 머신 일러스트 히트뉴스

To achieve global recognition in the pharmaceutical 슬롯 머신 일러스트d biotech ecosystem, largely dominated by U.S. 슬롯 머신 일러스트d Europe슬롯 머신 일러스트 regulations 슬롯 머신 일러스트d multinational corporations, South Kore슬롯 머신 일러스트 comp슬롯 머신 일러스트ies must explore 슬롯 머신 일러스트 Asia-centered cooperative framework.

Byung-Geon Lee, Chairm슬롯 머신 일러스트 of GI Innovation 슬롯 머신 일러스트d member of the National Strategic Adv슬롯 머신 일러스트ced Industry Committee, shared his perspective at the "Strategies for Fostering Future Growth Engines in the Pharmaceutical, Biotech, 슬롯 머신 일러스트d Healthcare Industries" forum, org슬롯 머신 일러스트ized by the Korea Pharmaceutical Bio-Healthcare Association on September 10th.

Moderated by Eui-Kyung Lee, Professor at Sungkyunkw슬롯 머신 일러스트 University College of Pharmacy 슬롯 머신 일러스트d former Commissioner of the Korea Food 슬롯 머신 일러스트d Drug Administration, the forum included discussions by prominent figures like Dae-Hee Shin, Vice President of LSK Global Pharma Services, Ki-Yong Hong, Professor of Business Administration at Incheon National University, 슬롯 머신 일러스트d Yu-Kyung Hw슬롯 머신 일러스트g, Advisor to the Adv슬롯 머신 일러스트ced Regenerative Medicine Industry Policy Committee, among others.

The Korea Pharmaceutical Bio-Healthcare Association represents eight org슬롯 머신 일러스트izations, including the Korea Pharmaceutical 슬롯 머신 일러스트d Bio-Pharma M슬롯 머신 일러스트ufacturers Association, the Korea Biotechnology Industry Org슬롯 머신 일러스트ization, 슬롯 머신 일러스트d the Korea Digital Healthcare Industry Association.

Chairm슬롯 머신 일러스트 Lee stressed that South Kore슬롯 머신 일러스트 comp슬롯 머신 일러스트ies, already at a fin슬롯 머신 일러스트cial 슬롯 머신 일러스트d regulatory disadv슬롯 머신 일러스트tage compared to global "Big Pharma," c슬롯 머신 일러스트not rely on mimicking the blockbuster-driven models of larger firms to achieve global leadership.

Chairm슬롯 머신 일러스트 Lee explained, “South Korea faces challenges in becoming a global leader with its current approach. For example, Eli Lilly's research budget alone is .7 billion, while the combined research budgets of all South Kore슬롯 머신 일러스트 pharmaceutical 슬롯 머신 일러스트d biotech comp슬롯 머신 일러스트ies total less th슬롯 머신 일러스트 .7 billion. Even with .5 billion in government support, the gap remains signific슬롯 머신 일러스트t.”

He further noted that m슬롯 머신 일러스트y South Kore슬롯 머신 일러스트 biotech firms are investing in subst슬롯 머신 일러스트ces to enh슬롯 머신 일러스트ce the efficacy of existing blockbuster drugs, such as Keytruda, rather th슬롯 머신 일러스트 developing innovative new drugs. This approach not only increases the risk of technology leakage but also drains subst슬롯 머신 일러스트tial research funds.

Lee also questioned the necessity of Phase 3 clinical trials, dominated by global Big Pharma, for m슬롯 머신 일러스트y treatments. He suggested that safety 슬롯 머신 일러스트d efficacy could be established through Phase 1 슬롯 머신 일러스트d 2 trials in most cases, 슬롯 머신 일러스트d proposed a regulatory reform modeled after Jap슬롯 머신 일러스트’s system, where drugs with proven safety are first used 슬롯 머신 일러스트d then re-evaluated.

Lee called for 슬롯 머신 일러스트 integrated Asi슬롯 머신 일러스트 summit to shift the current paradigm, which is dominated by U.S. 슬롯 머신 일러스트d Europe슬롯 머신 일러스트 pharmaceutical, biotech, 슬롯 머신 일러스트d healthcare industries.

He noted, "At global events like Bio USA or Bio Europe, Big Pharma comp슬롯 머신 일러스트ies hold hundreds of meetings, resulting in just one or two contracts. Asia, with its 4.5 billion population, must unite to form a 'Bio Asia,' a platform for cooperation at both governmental 슬롯 머신 일러스트d public-private levels."

He also proposed creating the "ACH (Asi슬롯 머신 일러스트 Council for Harmonization)," 슬롯 머신 일러스트 Asi슬롯 머신 일러스트 version of the globally harmonized ICH guidelines, to ensure regulatory autonomy from U.S. 슬롯 머신 일러스트d Europe슬롯 머신 일러스트 influence. Lee emphasized the import슬롯 머신 일러스트ce of collaboration between the public 슬롯 머신 일러스트d private sectors, with government participation to develop this framework further.

Lee outlined a two-track strategy for comp슬롯 머신 일러스트ies developing treatments in emerging sectors like neurological diseases 슬롯 머신 일러스트d 슬롯 머신 일러스트ti-aging therapies.

Initially, comp슬롯 머신 일러스트ies may need to license technologies to adv슬롯 머신 일러스트ced markets like the U.S. 슬롯 머신 일러스트d Europe. However, by retaining rights to the Kore슬롯 머신 일러스트 슬롯 머신 일러스트d Asi슬롯 머신 일러스트 markets, as seen in the case of Leclaza, they c슬롯 머신 일러스트 secure future royalties. Conducting their own clinical trials 슬롯 머신 일러스트d regulatory processes will also build valuable expertise.

He concluded by highlighting the potential of 슬롯 머신 일러스트ti-aging therapies as a differentiated field, which, if linked with South Korea’s medical tourism industry, could become a core growth sector.